Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd. (RCE) is a biotechnology company focused on the development and commercialization of innovative anti-infective therapies. The company specializes in creating synthetic polymers to combat serious infections, particularly those caused by antibiotic-resistant bacteria. Recce's lead product candidate, RECCE 327, is designed to treat a range of infections, including sepsis, and is positioned to address the growing global health challenge of antibiotic resistance.